| 8.05 0.13 (1.64%) | 11-11 14:32 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 9.97 | 1-year : | 11 |
| Resists | First : | 8.54 | Second : | 9.42 |
| Pivot price | 7.68 |
|||
| Supports | First : | 7.11 | Second : | 5.92 |
| MAs | MA(5) : | 7.54 |
MA(20) : | 7.89 |
| MA(100) : | 7.64 |
MA(250) : | 9.27 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 42.7 |
D(3) : | 25 |
| RSI | RSI(14): 52.7 |
|||
| 52-week | High : | 19 | Low : | 6.11 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GYRE ] has closed below upper band by 34.7%. Bollinger Bands are 4.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.06 - 8.1 | 8.1 - 8.14 |
| Low: | 7.34 - 7.39 | 7.39 - 7.44 |
| Close: | 7.83 - 7.92 | 7.92 - 8 |
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Tue, 11 Nov 2025
Calculating The Intrinsic Value Of Gyre Therapeutics, Inc. (NASDAQ:GYRE) - simplywall.st
Mon, 10 Nov 2025
Gyre Therapeutics (Nasdaq: GYRE) Healthcare Stocks Performance Amid S&P 500 - Kalkine Media
Mon, 10 Nov 2025
Is Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE Of 8.6% Concerning? - Yahoo Finance
Mon, 10 Nov 2025
What recovery options are there for Gyre Therapeutics Inc. - 2025 Geopolitical Influence & Long Hold Capital Preservation Tips - newser.com
Fri, 07 Nov 2025
Gyre Therapeutics Reports Strong Q3 2025 Results - TipRanks
Fri, 07 Nov 2025
Gyre Therapeutics Inc expected to post earnings of 4 cents a share - Earnings Preview - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 91 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 87.1 (%) |
| Held by Institutions | 3.7 (%) |
| Shares Short | 1,500 (K) |
| Shares Short P.Month | 1,620 (K) |
| EPS | 0.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1 |
| Profit Margin | 4 % |
| Operating Margin | 8.1 % |
| Return on Assets (ttm) | 4.2 % |
| Return on Equity (ttm) | 7.8 % |
| Qtrly Rev. Growth | 6 % |
| Gross Profit (p.s.) | 1.07 |
| Sales Per Share | 1.12 |
| EBITDA (p.s.) | 0.12 |
| Qtrly Earnings Growth | -62.8 % |
| Operating Cash Flow | 1 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | 394.25 |
| PEG Ratio | 0 |
| Price to Book value | 7.8 |
| Price to Sales | 7 |
| Price to Cash Flow | 772.59 |
| Dividend | 3.59 |
| Forward Dividend | 0 |
| Dividend Yield | 45.6% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|